SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. · DEFA14A filed Mar 27, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 2/10

DEFA14A filed Mar 27, 2026 at 16:30 ET

Ultragenyx Pharmaceutical Inc. (RARE) has filed a definitive additional proxy soliciting material (DEFA14A) for its 2026 Annual Meeting. The filing is routine and contains standard voting instructions for shareholders, including a notice to vote on proposals by May 13, 2026, and information on how to access meeting materials. There is no material financial data or significant corporate action disclosed.

  • Filing is a DEFA14A, which is a definitive additional proxy soliciting material.
  • It is for the 2026 Annual Meeting of shareholders.
  • The document contains a notice to vote by May 13, 2026, and instructions on how to access the proxy statement and annual report.
  • The filing is routine and does not contain any new financial information or significant corporate announcements.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access